종양학 임상시험 시장 : 단계 유형별, 연구 디자인별, 지역별 - 시장 규모, 산업 역학, 기회 분석, 예측(2026-2035년)

The global oncology clinical trials market is witnessing substantial growth, reflecting the increasing focus on developing new and effective cancer treatments. Valued at approximately USD 14.95 billion in 2025, the market is projected to expand significantly, reaching an estimated valuation of USD 25.61 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 5.53% over the forecast period from 2026 to 2035, highlighting the sustained momentum and investment flowing into oncology drug development.

Several key factors are driving this robust expansion. One of the primary contributors is the rising incidence of cancer worldwide, which has prompted greater demand for innovative therapies and accelerated clinical research efforts. As cancer rates climb due to aging populations and changing environmental and lifestyle factors, the urgency to discover and bring forward new treatment options intensifies.

Noteworthy Market Developments

The oncology clinical trials market is highly competitive and dynamic, marked by intense rivalry among leading pharmaceutical companies as well as a trend towards aggressive consolidation and the formation of strategic partnerships. This competitive environment reflects the high stakes involved in developing groundbreaking cancer therapies and the significant financial rewards that come with successful drug approvals. Major players in this arena, such as AstraZeneca, Merck & Co., Roche, and Novartis, have established themselves as dominant forces.

By 2025, these top-tier companies have collectively secured control over approximately 35% of the total oncology clinical trial pipeline, underscoring their influential role in shaping the future of cancer treatment. Their dominance is not only a result of their financial resources and scientific expertise but also a reflection of their strategic approaches to drug development and market penetration.

• AstraZeneca, for example, has carved out a leadership position in the rapidly evolving Antibody-Drug Conjugate (ADC) segment of oncology. This success is largely attributed to Enhertu, a breakthrough ADC that has demonstrated significant clinical benefits across multiple cancer types.
• Core Growth Drivers
• The increasing global prevalence of cancer has become a pressing healthcare challenge, significantly fueling the demand for faster development of new and effective treatments. As cancer incidence rates continue to rise worldwide due to factors such as aging populations, lifestyle changes, and environmental influences, the urgency to discover and bring innovative therapies to market has intensified. This growing burden of cancer not only impacts patient outcomes but also places immense pressure on healthcare systems to provide timely and effective interventions.
• Emerging Opportunity Trends
• AI-driven technologies are rapidly transforming key aspects of oncology clinical trials, particularly in the areas of patient recruitment, protocol design, and data management. These advanced technologies offer new opportunities to address longstanding challenges and inefficiencies that have traditionally hindered the pace and success of clinical research. By leveraging artificial intelligence, trial sponsors and researchers can now streamline complex processes, enhance precision, and optimize resource allocation, ultimately contributing to improved overall efficiency.
• Barriers to Optimization
• Patient recruitment continues to be the most significant challenge facing the oncology clinical trials market. Despite the critical importance of enrolling sufficient participants to ensure the validity and success of trials, historically, only a small fraction of adult cancer patients-less than 5%-have participated in clinical research. This low enrollment rate poses a major bottleneck in the drug development process, slowing progress and limiting the ability to gather comprehensive data on new treatments.

Detailed Market Segmentation

By phase type, the Phase III studies emerge as the most financially significant segment, representing over 48.89% of the total revenue share. This considerable dominance is largely due to the scale and complexity inherent in Phase III trials, which serve as the pivotal step before a new therapy can receive regulatory approval. Unlike earlier phases, Phase III trials typically involve enrolling a much larger patient population, averaging around 479 participants per study. These trials are conducted across hundreds of sites worldwide, reflecting their global scope and the need to gather extensive data from diverse patient groups to ensure the treatment's safety and efficacy.

By study design, the interventional studies segment holds a commanding position, accounting for more than 71% of the total revenue share within the clinical trials market. This dominance is largely attributable to the intricate and resource-intensive nature of investigational product (IP) dosing intrinsic to interventional studies. Unlike observational studies, which typically involve monitoring and data collection with minimal intervention, interventional trials require meticulous planning, administration, and management of therapeutic agents. These complexities drive higher costs and greater logistical challenges, including the need for specialized personnel, stringent regulatory compliance, and robust patient monitoring protocols, all of which contribute significantly to the revenue generated by this segment.

Segment Breakdown

By Phase Type

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design

• Interventional Studies
• Observational Studies
• Expanded Access Studies

By Region

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• South America

Geography Breakdown

• North America stands at the forefront of the global oncology clinical trials market, accounting for a dominant share of over 58% of radiation oncology studies as of early 2024. This leadership position underscores the region's significant influence in some of the most lucrative and cutting-edge segments within oncology, particularly radiopharmaceuticals and advanced cellular therapies. The strong presence of world-class research institutions, substantial funding, and a robust regulatory framework contribute to this dominance, fostering an environment conducive to innovation and rapid development of new cancer treatments.
• Data from recent years highlights the explosive growth in clinical research activities across North America. The total number of registered clinical studies in the region has surged dramatically, increasing from 477,200 in 2023 to an impressive 520,874 by late 2024. Within this vast research landscape, oncology interventions represent a substantial portion, with 68,453 trials dedicated to testing new cancer therapies and approaches. This significant volume of oncology trials reflects both the urgency of addressing cancer as a major health challenge and the region's capacity to conduct complex, large-scale studies.

Leading Market Participants

• AbbVie Inc.
• AstraZeneca PLC
• BeiGene Ltd.
• Bristol Myers Squibb
• Charles River Laboratories
• Clovis Oncology
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• IQVIA
• ICON plc
• Johnson & Johnson
• Labcorp Drug Development
• Medpace Holdings
• Merck & Co., Inc.
• Novartis AG
• Parexel International
• Pfizer Inc.
• Syneos Health
• Takeda Pharmaceutical
• Thermo Fisher Scientific
• Wuxi Clinical CRO
• Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Oncology Clinical Trials Market

Chapter 2. Report Description

• 2.1. Research Framework
  • 2.1.1. Research Objective
  • 2.1.2. Market Definitions
  • 2.1.3. Market Segmentation
• 2.2. Research Methodology
  • 2.2.1. Market Size Estimation
  • 2.2.2. Qualitative Research
    • 2.2.2.1. Primary & Secondary Sources
  • 2.2.3. Quantitative Research
    • 2.2.3.1. Primary & Secondary Sources
  • 2.2.4. Breakdown of Primary Research Respondents, By Region
  • 2.2.5. Data Triangulation
  • 2.2.6. Assumption for Study

Chapter 3. Global Oncology Clinical Trials Market Overview

• 3.1. Industry Value Chain Analysis
  • 3.1.1. Drug Discovery & Preclinical Development
  • 3.1.2. Clinical Trial Planning & Regulatory Approval
  • 3.1.3. Clinical Trial Execution & Patient Recruitment
  • 3.1.4. Clinical Trial Supply & Logistics
  • 3.1.5. Data Analysis & Regulatory Submission
  • 3.1.6. Commercialization
• 3.2. Industry Outlook
  • 3.2.1. Growing Oncology Drug Pipeline
  • 3.2.2. Increasing Cancer Incidence Globally
  • 3.2.3. Rising Outsourcing to CROs
  • 3.2.4. Increasing Adoption of Precision Medicine
  • 3.2.5. Regulatory Support for Oncology Trials
• 3.3. PESTLE Analysis
• 3.4. Porter's Five Forces Analysis
  • 3.4.1. Bargaining Power of Suppliers
  • 3.4.2. Bargaining Power of Buyers
  • 3.4.3. Threat of Substitutes
  • 3.4.4. Threat of New Entrants
  • 3.4.5. Degree of Competition
• 3.5. Market Growth and Outlook
  • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.5.2. Pricing Analysis, By Phase Type
• 3.6. Market Attractiveness Analysis
  • 3.6.1. By Phase Type
• 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

• 4.1. Market Concentration Rate
• 4.2. Company Market Share Analysis (Value %), 2025
• 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Oncology Clinical Trials Market Analysis

• 5.1. Market Dynamics and Trends
  • 5.1.1. Growth Drivers
  • 5.1.2. Restraints
  • 5.1.3. Opportunity
  • 5.1.4. Key Trends
• 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 5.2.1. By Phase Type
    • 5.2.1.1. Key Insights
      • 5.2.1.1.1. Phase I
      • 5.2.1.1.2. Phase II
      • 5.2.1.1.3. Phase III
      • 5.2.1.1.4. Phase IV
  • 5.2.2. By Study Design
    • 5.2.2.1. Key Insights
      • 5.2.2.1.1. Interventional Studies
      • 5.2.2.1.2. Observational Studies
      • 5.2.2.1.3. Expanded Access Studies
  • 5.2.3. By Region
    • 5.2.3.1. Key Insights
      • 5.2.3.1.1. North America
        • 5.2.3.1.1.1. The U.S.
        • 5.2.3.1.1.2. Canada
        • 5.2.3.1.1.3. Mexico
      • 5.2.3.1.2. Europe
        • 5.2.3.1.2.1. Western Europe
          • 5.2.3.1.2.1.1. The UK
          • 5.2.3.1.2.1.2. Germany
          • 5.2.3.1.2.1.3. France
          • 5.2.3.1.2.1.4. Italy
          • 5.2.3.1.2.1.5. Spain
          • 5.2.3.1.2.1.6. Rest of Western Europe
        • 5.2.3.1.2.2. Eastern Europe
          • 5.2.3.1.2.2.1. Poland
          • 5.2.3.1.2.2.2. Russia
          • 5.2.3.1.2.2.3. Rest of Eastern Europe
      • 5.2.3.1.3. Asia Pacific
        • 5.2.3.1.3.1. China
        • 5.2.3.1.3.2. India
        • 5.2.3.1.3.3. Japan
        • 5.2.3.1.3.4. South Korea
        • 5.2.3.1.3.5. Australia & New Zealand
        • 5.2.3.1.3.6. ASEAN
          • 5.2.3.1.3.6.1. Indonesia
          • 5.2.3.1.3.6.2. Malaysia
          • 5.2.3.1.3.6.3. Thailand
          • 5.2.3.1.3.6.4. Singapore
          • 5.2.3.1.3.6.5. Rest of ASEAN
        • 5.2.3.1.3.7. Rest of Asia Pacific
      • 5.2.3.1.4. Middle East & Africa
        • 5.2.3.1.4.1. UAE
        • 5.2.3.1.4.2. Saudi Arabia
        • 5.2.3.1.4.3. South Africa
        • 5.2.3.1.4.4. Rest of MEA
      • 5.2.3.1.5. South America
        • 5.2.3.1.5.1. Argentina
        • 5.2.3.1.5.2. Brazil
        • 5.2.3.1.5.3. Rest of South America

Chapter 6. North America Oncology Clinical Trials Market Analysis

• 6.1. Market Dynamics and Trends
  • 6.1.1. Growth Drivers
  • 6.1.2. Restraints
  • 6.1.3. Opportunity
  • 6.1.4. Key Trends
• 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 6.2.1. By Phase Type
  • 6.2.2. By Study Design
  • 6.2.3. By Country

Chapter 7. Europe Oncology Clinical Trials Market Analysis

• 7.1. Market Dynamics and Trends
  • 7.1.1. Growth Drivers
  • 7.1.2. Restraints
  • 7.1.3. Opportunity
  • 7.1.4. Key Trends
• 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 7.2.1. By Phase Type
  • 7.2.2. By Study Design
  • 7.2.3. By Country

Chapter 8. Asia Pacific Oncology Clinical Trials Market Analysis

• 8.1. Market Dynamics and Trends
  • 8.1.1. Growth Drivers
  • 8.1.2. Restraints
  • 8.1.3. Opportunity
  • 8.1.4. Key Trends
• 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 8.2.1. By Phase Type
  • 8.2.2. By Study Design
  • 8.2.3. By Country

Chapter 9. Middle East & Africa Oncology Clinical Trials Market Analysis

• 9.1. Market Dynamics and Trends
  • 9.1.1. Growth Drivers
  • 9.1.2. Restraints
  • 9.1.3. Opportunity
  • 9.1.4. Key Trends
• 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 9.2.1. By Phase Type
  • 9.2.2. By Study Design
  • 9.2.3. By Country

Chapter 10. South America Oncology Clinical Trials Market Analysis

• 10.1. Market Dynamics and Trends
  • 10.1.1. Growth Drivers
  • 10.1.2. Restraints
  • 10.1.3. Opportunity
  • 10.1.4. Key Trends
• 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 10.2.1. By Phase Type
  • 10.2.2. By Study Design
  • 10.2.3. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

• 11.1. AbbVie Inc.
• 11.2. AstraZeneca PLC
• 11.3. BeiGene Ltd.
• 11.4. Bristol Myers Squibb
• 11.5. Charles River Laboratories
• 11.6. Clovis Oncology
• 11.7. Eli Lilly and Company
• 11.8. F. Hoffmann-La Roche Ltd
• 11.9. IQVIA
• 11.10. ICON plc
• 11.11. Johnson & Johnson
• 11.12. Labcorp Drug Development
• 11.13. Medpace Holdings
• 11.14. Merck & Co., Inc.
• 11.15. Novartis AG
• 11.16. Parexel International
• 11.17. Pfizer Inc.
• 11.18. Syneos Health
• 11.19. Takeda Pharmaceutical
• 11.20. Thermo Fisher Scientific
• 11.21. Wuxi Clinical CRO
• 11.22. Other Prominent Players

Chapter 12. Annexure

• 12.1. List of Secondary Sources
• 12.2. Key Country Markets- Macro Economic Outlook/Indicators